Report of a meeting; molecular basis of cancer therapy

Journal of the National Cancer Institute

Volumn 86, Issue 17, 1994, Pages 1277-1285

  Gottesman, Michael M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN;

APOPTOSIS; CELL CYCLE; CONFERENCE PAPER; DRUG RESISTANCE; GENE THERAPY; GENETICS; HUMAN; METASTASIS; NEOPLASM; ONCOGENE; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANTIGENS, NEOPLASM; APOPTOSIS; CELL CYCLE; DRUG RESISTANCE; GENE THERAPY; GENES, TUMOR SUPPRESSOR; HUMAN; NEOPLASM METASTASIS; NEOPLASMS; ONCOGENES; SIGNAL TRANSDUCTION;

EID: 0028767592     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/86.17.1277     Document Type: Article

References (49)

1. multiplication [editorial]. Curr Opin Cell Biol 5:163-165,1993
2. Solomon MJ, Lee T, Kirschner MW: Role of phosphorylation in p34cdc2 activation: Identification of an activating kinase. Mol Biol Cell 3:13-27, 1992
3. Glotzer M, Murray AW, Kirschner MW: Cyclin is degraded by the ubiquitin pathway [see comment citations in Medline], Nature 349:132-138, 1991
4. Hengst L, Dulic V, Slingerland JM, et al: A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl AcadSci U S A 91:5291-5295, 1994
5. Dulic V, Kaufmann WK, Wilson SJ, et al: P53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013-1023, 1994
6. Slingerland JM, Hengst L, Pan CH, et al: A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells. Mol Cell Biol 14:3683-3694, 1994
7. Resnitzky D, Gossen M, Bujard H, et al: Acceleration of the Gl/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 14:1669-1679, 1994
8. Lowy DR, Willumsen BM: Function and regulation of ras. Annu Rev Biochem 62:851-891, 1993
9. Levine AJ: The tumor suppressor genes. Annu Rev Biochem 62:623-651, 1993
10. Johnson MR, DeClue JE, Felzmann S, et al: Neurofibromin can inhibit Ras-dependent growth by a mechanism independent of its GTPase-ac-celerating function. Mol Cell Biol 14:641-645, 1994
11. Bargonetti J, Manfredi JJ, Chen X, et al: A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev 7:2565-2574, 1993
12. Anderson LA, Friedman L, Osbome-Lawrence S, et al: High-density genetic map of the BRCA1 region of chromosome 17ql2-q21. Genomics 17:618-623,1993
13. Edery P, Lyonnet S, Mulligan LM, et al: Mutations of the RET proto-oncogene in Hirschsprung’s disease. Nature 367:378-380, 1994
14. Gudkov AV, Zelnick CR, Kazarov AR, et al: Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad Sci U S A 90:3231-3235,1993
15. Gudkov AV, Kazarov AR, Thimmapaya R, et al: Cloning mammalian genes by expression selection of genetic suppressor elements: association of kinesin with drug resistance and cell immortalization. Proc Natl Acad Sci U S A 91:3744-3748, 1994
16. Gibbs JB, Oliff A, Kohl NE: Famesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 77:175-178, 1994
17. Kohl NE, Mosser SD, deSolms SJ, et al: Selective inhibition of ras-dependent transformation by a famesyltransferase inhibitor. Science 260:1934-1937,1993
18. Prendergast GC, Davide JP, deSolms SJ, et al: Famesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol 14:4193-4202, 1994
19. Schimke RT, Mihich E: Fifth annual Pezcoller symposium: apoptosis. Cancer Res 54:302-305, 1994
20. Stewart BW: Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators. J Natl Cancer Inst 86:1286-1296, 1994.
21. Lowe SW, Schmitt EM, Smith SW, et al: p53 is required for radiation -induced apoptosis in mouse thymocytes. Nature 362:847-849, 1993
22. Low SW, Jacks T, Housman DE, et al: Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc Natl Acad Sci US A 91:2026-2030, 1994
23. Shattil SJ, Haimovich B, Cunningham M, et al: Tyrosine phosphorylation of ppl25FAK in platelets requires coordinated signaling through integrin and agonist receptors. J Biol Chem 269:14738-14745. 1994
24. Wame PH, Viciana PR, Downward J: Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro. Nature 364:352-355, 1993
25. Hallberg B, Rayter SI, Downward J: Interaction of Ras and Raf in intact mammalian cells upon extracellular stimulation. J Biol Chem 269:3913-3916,1994
26. Witte ON: Role of the BCR-ABL oncogene in human leukemia: fifteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 53:485-489,1993
27. Afar DE, Goga A, McLaughlin J, et al: Differential complementation of Bcr-Abl point mutants with c-Myc. Science 264:424-426, 1994
28. Gizang-Ginsberg E, Ziff EB: Fos family members successively occupy the tyrosine hydroxylase gene AP-1 site after nerve growth factor or epidermal growth factor stimulation and can repress transcription. Mol Endocrinol 8:249-262, 1994
29. Gottesman MM, Pastan 1: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427, 1993
30. Piekarz RL, Cohen D, Horwitz SB: Progesterone regulates the murine multidrug resistance mdrlb gene. J Biol Chem 268:7613-7616, 1993
31. Smit JJ, Schinkel AH, Oude Elferink RP, et al: Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75:451-462, 1993
32. Schinkel AH, Smit JJ, Van Telingen O, et al: Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502, 1994
33. Dalton WS, Salmon SE: Drug resistance in myeloma: mechanisms and approaches to circumvention. Hematol Oncol Clin North Am 6:383-393, 1992
34. Sikic BI: Modulation of multidrag resistance: at the threshold, [editorial, comment]. J Clin Oncol 11:1629-1635, 1993
35. Cole SP, Bhardwaj G, Gerlach JH, et al: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654,1992
36. Grant CE, Valdimarsson G, Hipfner DR, et al: Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54:357-361, 1994
37. Graham CH, Kobayashi H, Stankiewicz KS, et al: Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents. J Natl Cancer Inst 86:975-982, 1994
38. Kobayashi H, Man S, Graham CH, et al: Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci U S A 90:3294-3298,1993
39. Plate KH, Breier G, Weich HA, et al: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845-848,1992
40. Millauer B, Shawver LK, Plate KH, et al: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367:576-579, 1994
41. Stetler-Stevenson WG, Aznavoorian S, Liotta LA: Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9:541-573, 1993
42. Moses MA, Shing Y: Production of matrix metalloproteinases and a metalloproteinase inhibitor by swarm rat chondrosarcoma. Biochem Biophys Res Commun 199:418-424, 1994
43. Pastan I, Chaudhary V, FitzGerald DJ: Recombinant toxins as novel therapeutic agents. Annu Rev Biochem 61:331-354, 1992
44. Waldmann TA: Lymphokine receptors: a target for immunotherapy of lymphomas. Ann Oncol 5:S 13-S17, 1994
45. Bamford RN, Grant AJ, Burton JD, et al: The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A 91:4940-4944, 1994
46. Pardoll DM: New strategies for enhancing the immunogenicity of tumors. Curr Opin Immunol 5:719-725, 1993
47. Gottesman MM, Germann UA, Aksentijevich I, et al: Gene transfer of drug resistance genes: implications for cancer therapy. Ann NY Acad Sci 716:126-139, 1994
48. Yu D, Shi D, Scanlon M, et al: Reexpression of neu-encoded oncoproetin counteracts the tumor-suppressing but not the metastasis-suppressing function of E1 A. Cancer Res 53:5784-5790, 1993
49. Maxwell H, Glode LM, Maxwell F: Expression of diphtheria toxin A-chain in mature B-cells: a potential approach to therapy of B-ymphoid malignancy. Leuk Lymphoma 7:457-462, 1992